Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis

OBJECTIVE: Candida species are responsible for fungal diseases and the development of nosocomial bloodstream infections. Treatment is resource-intensive and economically challenging for healthcare systems. Cost analyses of drugs against candidiasis, such as rezafungin, are thus of great interest to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeck, Julia, Jakobs, Florian, Kurte, Melina S, Cornely, Oliver A, Kron, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279419/
https://www.ncbi.nlm.nih.gov/pubmed/37342199
http://dx.doi.org/10.1093/jacamr/dlad079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279419/
https://www.ncbi.nlm.nih.gov/pubmed/37342199
http://dx.doi.org/10.1093/jacamr/dlad079

Ejemplares similares